Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Decrease in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant drop in short interest in June. As of June 15th, there was short interest totaling 4,540 shares, a drop of 90.0% from the May 31st total of 45,360 shares. Based on an average daily volume of 92,782 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Sonoma Pharmaceuticals has an average rating of “Sell”.

Sonoma Pharmaceuticals Trading Down 0.9%

Shares of Sonoma Pharmaceuticals stock opened at $1.14 on Friday. The business’s fifty day simple moving average is $1.28 and its 200 day simple moving average is $2.39. The firm has a market capitalization of $5.46 million, a P/E ratio of -0.60 and a beta of 1.29. Sonoma Pharmaceuticals has a 12 month low of $0.85 and a 12 month high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings data on Tuesday, June 16th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative net margin of 16.26% and a negative return on equity of 43.95%. The business had revenue of $5.56 million during the quarter, compared to the consensus estimate of $5.57 million.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. acquired a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned about 0.66% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.